Monday, July 05, 2010 - AstraZeneca secures deal with academia

AstraZeneca, the Anglo-Swedish pharmaceutical company, is to share many of its experimental drug compounds with academic researchers, in a deal that will give it privileged access to early-stage science.

The company will combine up to 100,000 compounds from its proprietary “library” with 50,000 controlled by the commercial spin-off arm of the UK’s Medical Research Council, the government-backed funder of academic science.


Posted via email from Jack's posterous

No comments: